GLAXOSMITH • NSE
Glaxo Smithkline Consumer Nigeria Plc
Open Price
Previous Close
Today’s Range
-
Number of Deals
Volume Traded
Value Traded
52 Weeks High
52 Weeks Low
Market Cap
20,329,900,296.00
YTD Price Performance
155.64 %
NGX Delists GlaxoSmithKline Consumer Nigeria Plc from Its Daily Official List
NGX Places the Shares of Glaxo SmithKline Consumer Nigeria Plc on Suspension in Preparation for its Delisting
Glaxosmithkline Consumer Nigeria Plc Receives SEC Approval and Court Sanction to Delist from NGX
Glaxosmithkline Consumer Nigeria Plc Declares N340mln PAT in Q2 2023 Results,(SP:N8.2K)
GlaxoSmithKline Consumer Nigeria Plc to Cease Operations
Glaxo SmithKline Consumer Nigeria Plc Notifies on Resolutions Passed at Extraordinary General Meeting
GlaxoSmithKline Consumer Nigeria Plc Reports N483.54m PAT in Q3'22 Unaudited Results; (SP: N6.25K)
GlaxoSmithKline Consumer Nigeria Plc to Hold Board Meeting on July 28, 2022; Declares Closed Period
Glaxosmithkline Consumer Nigeria Plc Announces Resolutions Passed at 51st AGM
GLAXOSMITH declares N194m PAT in Q1'22 Result;(SP:N5.85K)
Shares Outstanding
1,195,876,488.00
Net Assets
9,214.00
Book Value Per Share
7.70
Sector P/E
57.84
EPS
0.28
P/E
60.71
ROE
0.00
Dividend Yield
3.24
Sector
Healthcare
Sub Sector
Pharmaceutical
Management
Mark Pfister
Mr. Kunle Oyelana
Bosco Kirugi
Address
"1 Industrial Avenue, Ilupeju Lagos"
Phone No
" +234 1 2711000 +234 1 3424900"
Email Address
Website
https://ng.gsk.com/en-gb/
Board of Directors
Mr. Samuel Kuye
Mr. Kunle Oyelana
Mrs. Oludewa Edodo-Thorpe
Oussama Abbas
Mr. Edmund C. Onuzo
Mark Pfister
Social Media Accounts
Subsidiary
Winster Pharmaceutical Limited
Company Secretary
Mr. Uche Uwechia
End of Accounting Year
31 Dec
Listing Date
01/07/1979
Company Registrar
Greenwich Registrars & Data Solutions Limited, UNION REGISTRARS LIMITED
Regulatory Status
CG+
Free Float
0.00
Auditor
Touche
Q2 Unaudited Financial Statements for the Period ended 30th June 2023 - GLAXOSMITHKLINE CONSUMER NIGERIA PLC
August 7th, 2023 at 4:34 PM
2021 Audited Financial Statements for the Period ended 31st December 2021 –GlaxoSmithKline Consumer Nigeria Plc
May 8th, 2022 at 2:47 PM
Q4 2021 Unaudited Financial Statements for the Period ended 31st December 2021 – GlaxoSmithKline Consumer Nigeria Plc
April 4th, 2022 at 12:00 AM
Q2, 2023 and Q2, 2022 Financial Performance Comparison
Profit & loss information
Description | Q 2, 2023 N'm | Q 2, 2022 N'm | % Change |
---|---|---|---|
Gross Earnings | 0.00 | 0.00 | + 0.00% |
Profit Before Tax | 504.00 | 518.00 | -2.70% |
Income Tax Expense | -164.00 | -168.00 | -2.38% |
Taxation | -164.00 | -168.00 | -2.38% |
Profit After Tax | 340.00 | 349.00 | -2.58% |
Fixed Assets | 349.00 | 495.00 | -29.49% |
Total Assets | 30,268.00 | 26,535.00 | + 14.07% |
Customers Deposits | 0.00 | 0.00 | + 0.00% |
Loans and Advances | 0.00 | 0.00 | + 0.00% |
Total Liabilities | 21,054.00 | 17,425.00 | + 20.83% |
Borrowings | 0.00 | 0.00 | + 0.00% |
Cash Flow From Operating Activities | 0.00 | 0.00 | + 0.00% |
Description | Q 2, 2023 N'm | Q 1, 2023 N'm | Q 2, 2022 N'm | Q 4, 2021 N'm | Q 3, 2021 N'm | Trend |
---|---|---|---|---|---|---|
Gross Earnings | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Gross Premium Written | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Revenue | 7,751.00 | 4,019.00 | 14,811.00 | 22,450.00 | 6,590.00 | |
Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Interest And Similar Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Gross Premium Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Cost Of Sales | -4,958.00 | -2,541.00 | -11,067.00 | -16,270.00 | -4,997.00 |
Description | Q 2, 2023 N'm | Q 1, 2023 N'm | Q 2, 2022 N'm | Q 4, 2021 N'm | Q 3, 2021 N'm | Trend |
---|---|---|---|---|---|---|
Property Plant And Equipment | 349.00 | 419.00 | 495.00 | 540.00 | 1,729.00 | |
Fair Value Movements On Equity Instruments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Value Through Profit Or Loss | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Intangible Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Fair Value Movements On Debt Securities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Management Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Other Non Current Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Description | Q 2, 2023 N'm | Q 1, 2023 N'm | Q 2, 2022 N'm | Q 4, 2021 N'm | Q 3, 2021 N'm | Trend |
---|---|---|---|---|---|---|
Cash Flow From Operating Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Total Premium Received | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Receipt From Reinsurance Recovery | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Reinsurance Premium Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Profit For The Period | 340.00 | 155.00 | 349.00 | 0.00 | 0.00 | |
Commission Received | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Claims Recoveries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Remark | Date |
---|---|
To consider the full year Audited Financial Statements for the Year ended 31st December 2021, and issues around dividend. | 3/16/2022 |
To consider the 2013 Audited Financial Statements and the amount to be recommended to members as final dividend at the next Annual General Meeting | 3/7/2014 |
To consider and approve the company's Audited Financial Statements for the year ended December 31, 2011. To consider the amount to be recommended to members as dividend at its next Annual General Meeting (AGM) and also fix a date and venue for the forth coming general meeting. | 2/23/2012 |
To consider and approve its 2010 Audited Financial Statements. | 2/28/2011 |
Dividend | Dividend Type | Announement Date | Payment Date | Date |
---|---|---|---|---|
0.55 | Final | 5/25/2020 | 7/24/2020 | 6/23/2020 |
0.50 | Final | 3/8/2019 | 5/24/2019 | 4/22/2019 |
0.40 | Final | 3/19/2018 | 5/25/2018 | 4/23/2018 |
0.30 | Final | 3/16/2016 | 6/24/2016 | 5/25/2016 |
0.75 | Final | 4/1/2015 | 6/12/2015 | 5/14/2015 |
1.30 | Final | 3/11/2014 | 6/12/2014 | 5/16/2014 |
1.30 | Final | 3/26/2013 | 5/24/2013 | 4/23/2013 |
1.20 | Final | 2/27/2012 | 5/23/2012 | 4/24/2012 |
0.90 | Final | 3/4/2011 | 4/29/2011 | |
0.75 | Final | 3/1/2010 | 4/30/2010 |
Bonus | Bonus Type | Announement Date | Payment Date | Date |
---|---|---|---|---|
1 for 4 | 1 for 4 | 4/1/2015 | 4/14/2015 | |
1 for 5 | 1 for 5 | 5/6/2005 |
New Face Value | Old Face Value | Exsplit Date | Announement Date |
---|
Book Closure | Address | Announement Date | Date |
---|---|---|---|
6/23/2020 | GSK House, 1, Induthrial Avenue, Ilupeju, Lagos | 5/25/2020 | 7/23/2020 |
4/23/2019 | MUSON Centre, Onikan, Lagos | 3/8/2019 | 5/23/2019 |
4/24/2018 | The Shell Nigeria Hall, Muson Center,onikan , lagos | 3/19/2018 | 5/24/2018 |
5/25/2016 | Muson Center, Onikan , Lagos | 3/16/2016 | 6/23/2016 |
5/14/2015 | To be advised | 4/1/2015 | 6/11/2015 |
5/16/2014 | N/A | 3/11/2014 | 6/11/2014 |
4/23/2013 | City Hall, Lagos at 11.00 a.m. | 3/26/2013 | 5/23/2013 |
4/24/2010 | MUSON Centre, Onikan Lagos at 11.00 a.m. | 2/27/2012 | 5/22/2012 |
4/29/2011 | 3/4/2011 | 5/24/2011 | |
4/28/2010 | 5/25/2010 |
Trend | R1 | R2 | R3 | PP | S1 | S2 | S3 |
---|---|---|---|---|---|---|---|
Classic | 1,565.72 | 1,565.72 | 1,565.72 | 1,565.72 | 1,565.72 | 1,565.72 | 1,565.72 |
Classic | 1,565.72 | 1,565.72 | 1,565.72 | 1,565.72 | 1,565.72 | 1,565.72 | 1,565.72 |
Classic | 1,565.72 | 1,565.72 | 1,565.72 | 1,565.72 | 1,565.72 | 1,565.72 | 1,565.72 |
Note: This is just a sample text, change appropriately.
Trend | R1 | R2 | R3 | PP | S1 | S2 | S3 |
---|---|---|---|---|---|---|---|
Classic | 1,565.72 | 1,565.72 | 1,565.72 | 1,565.72 | 1,565.72 | 1,565.72 | 1,565.72 |
Classic | 1,565.72 | 1,565.72 | 1,565.72 | 1,565.72 | 1,565.72 | 1,565.72 | 1,565.72 |
Classic | 1,565.72 | 1,565.72 | 1,565.72 | 1,565.72 | 1,565.72 | 1,565.72 | 1,565.72 |
Note: This is just a sample text, change appropriately.
Trend | R1 | R2 | R3 | PP | S1 | S2 | S3 |
---|---|---|---|---|---|---|---|
Classic | 1,565.72 | 1,565.72 | 1,565.72 | 1,565.72 | 1,565.72 | 1,565.72 | 1,565.72 |
Classic | 1,565.72 | 1,565.72 | 1,565.72 | 1,565.72 | 1,565.72 | 1,565.72 | 1,565.72 |
Classic | 1,565.72 | 1,565.72 | 1,565.72 | 1,565.72 | 1,565.72 | 1,565.72 | 1,565.72 |
Note: This is just a sample text, change appropriately.
Q 1, 2023
Q 2, 2023
Q 1, 2023
Q 2, 2023
Q 1, 2023
Q 2, 2023
Q 1, 2023
Q 2, 2023
Q 1, 2023
Q 2, 2023
Q 1, 2023
Q 2, 2023
Sponsored Ad Advertise with Us
Proshare is a professional practice focused on delivering research and information services to bridge the gap between investors and markets; by delivery on credible, reliable, and timely engagements through the following areas — Impact Research, Market Intelligence, Strategic Advisory, Stakeholder Relations & Digital Media.